I remain optimistic that the states will continue to see that the pros greatly outweigh the cons when it comes to the legalization of cannabis. There are some creative ways to indirectly benefit from the weed rush across the U.S.
We have updated the comparison of eight large cap biopharma stocks post 2016 earnings for the period ending 2/10/17. Keep in mind that in January 2016 there was a severe correction with stocks dropping 25-30% with lows being hit in February 2016.
Companies like Celgene, Biogen and AbbVie reported fourth quarter results last week. Catabasis suffered a major setback with its lead pipeline candidate edasalonexent failing to meet the primary endpoint.